Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs

References

• Rezkalla S, Kloner RA, Ensley J et al. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J. Clin. Oncol.7(4), 509–514 (1989).
   PubMed Web of Science ®Google Scholar
• Ewer MS, Vooletich MT, Durand JB et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol.23(31), 7820–7826 (2005).
   PubMed Web of Science ®Google Scholar
• deForni M, Malet-Martino MC, Jaillais P et al. Cardiotoxicity of high-dose infusional fluorouracil: a prospective clinical study. J. Clin. Oncol.10, 1795–1801 (1992).
   PubMed Web of Science ®Google Scholar
• Labianca R, Beretta G, Clerici M et al. Cardiac toxicity of 5- fluorouracil: a study on 1083 patients. Tumori68, 505–510 (1982).
   PubMed Web of Science ®Google Scholar
• Schober C, Papageorgiou E, Harstrick A et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer72, 2242–2247 (1993).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J. Clin. Oncol.9(9), 1704–1712 (1991).
   PubMed Web of Science ®Google Scholar
• Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol.20, 1215–1221 (2002).
   PubMed Web of Science ®Google Scholar
• Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest99, 557–561 (1991).
   PubMed Web of Science ®Google Scholar
• Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J. Clin. Oncol.21(19), 3609–3615 (2003).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349(5), 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol.23(4), 792–799 (2005).
   PubMed Web of Science ®Google Scholar
• Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43–9006. J. Clin. Oncol.24(9), 1363–1369 (2006).
   PubMed Web of Science ®Google Scholar
• Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol.23(31), 7811–7819 (2005).
   PubMed Web of Science ®Google Scholar
• Gietema JA, Sleijfer DT, Willemse PH et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann. Intern. Med.116(9), 709–715 (1992).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J. Clin. Oncol.14(11), 2923–2932 (1996).
   PubMed Web of Science ®Google Scholar
• Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol.18(8), 1725–1732 (2000).
   PubMed Web of Science ®Google Scholar
• Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol.21(8), 1513–1523 (2003).
   PubMed Web of Science ®Google Scholar
• van den Belt-Dusebout AW, Nuver J, de Wit R et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J. Clin. Oncol.24(3), 467–475 (2006).
   PubMed Web of Science ®Google Scholar
• Jensen SA, Sorensen JB. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother. Pharmacol.58, 487–493 (2006) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Tsavaris N, Kosmas C, Vadiaka M et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy – a survey of 427 patients. Med. Sci. Monit.8(6), PI51–P157 (2002).
   PubMedGoogle Scholar
• Meydan N, Kundak I, Yavuzsen T et al. Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Jpn. J. Clin. Oncol.35(5), 265–270 (2005).
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344, 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J. Clin. Oncol.23(10), 2396–2410 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenfeld CS, Broder LE. Cisplatin-induced autonomic neuropathy. Cancer Treat. Rep.68, 659–660 (1984).
   PubMedGoogle Scholar
• Crone SA, Zhao Y-Y, Fan L et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med.8, 459–465 (2002).
   PubMed Web of Science ®Google Scholar
• Labianca R, Luporini G. 5-fluorouracil cardiotoxicity: the risk of rechallenge. Ann. Oncol.2(5), 383 (1991).
   PubMed Web of Science ®Google Scholar
• Cianci G, Morelli MF, Cannita K et al. Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity. Br. J. Cancer88(10), 1507–1509 (2003).
   PubMed Web of Science ®Google Scholar
• White RL Jr, Schwartzentruber DJ, Guleria A et al. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer74(12), 3212–3222 (1994).
   PubMed Web of Science ®Google Scholar
• Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer71(2), 493–509 (1993).
   PubMed Web of Science ®Google Scholar
• Tsibiribi P, Descotes J, Lombard-Bohas C et al. Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Bull. Cancer93(3), E27–E30 (2006).
   Web of Science ®Google Scholar
• Grandi AM, Pinotti G, Morandi E et al. Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. Ann. Oncol.8(7), 705–708 (1997).
   PubMed Web of Science ®Google Scholar
• Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res.53(13), 3028–3033 (1993).
   PubMed Web of Science ®Google Scholar
• Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol.42(4), 304–308 (2003).
   PubMed Web of Science ®Google Scholar
• Sudhoff T, Enderle MD, Pahlke M et al. 5-Fluorouracil induces arterial vasocontractions. Ann. Oncol.15(4), 661–664 (2004).
   PubMed Web of Science ®Google Scholar
• Schnetzler B, Popova N, Collao Lamb C, Sappino AP. Coronary spasm induced by capecitabine. Ann. Oncol.12(5), 723–724 (2001).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann. Oncol.13(3), 484–485 (2002).
   PubMed Web of Science ®Google Scholar
• Kuppens IE, Boot H, Beijnen JH, Schellens JH, Labadie J. Capecitabine induces severe angina-like chest pain. Ann. Intern. Med.140(6), 494–495 (2004).
   PubMed Web of Science ®Google Scholar
• Frickhofen N, Beck FJ, Jung B et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann. Oncol.13, 797–801 (2002).
   PubMed Web of Science ®Google Scholar
• Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur. J. Cancer41(11), 1542–1546 (2005).
   PubMed Web of Science ®Google Scholar
• Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N. Capecitabine-induced severe hypertriglyceridemia: report of two cases. Ann. Pharmacother.40(2), 328–331 (2006).
   PubMed Web of Science ®Google Scholar
• Marcos Sanchez F, Albo Castano I, Arbol Linde F, Juarez Ucelay F, Duran Perez-Navarro A. (Cardiac toxicity and UFT). An. Med. Interna.20(1), 50 (2003). (Article in Spanish)
   PubMedGoogle Scholar
• Nakagawa Y, Ogawa N, Suzuki H, Miki H, Tominaga M, Takahashi M. A case of variant angina induced by 5-fluorouracil and Tegafur. Kokyu To Junkan.36(11), 1265–1268 (1988). (Article in Japanese)
   PubMedGoogle Scholar
• Kikuchi K, Majima S, Murakami M. Clinical survey on cardiotoxicity of tegafur (FT-207) – compilation of a nationwide survey. Gan To Kagaku Ryoho.9(8), 1482–1488 (1982). (Article in Japanese)
   PubMedGoogle Scholar
• Gianni L, Dombernowsky P, Sledge G et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann. Oncol.12(8), 1067–1073 (2001).
   PubMed Web of Science ®Google Scholar
• Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol.13(11), 2688–2699 (1995).
   PubMed Web of Science ®Google Scholar
• Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann. Oncol.7(7), 687–693 (1996).
   PubMed Web of Science ®Google Scholar
• Arbuck SG, Strauss H, Rowinsky EK et al. A reassessment of cardiac toxicity associated with Taxol. J. Natl Cancer Inst. Monogr.15, 117–130 (1993).
   PubMedGoogle Scholar
• Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors. J. Clin. Oncol.16(11), 3483–3485 (1998).
   PubMed Web of Science ®Google Scholar
• Perez EA. Paclitaxel and cardiotoxicity. J. Clin. Oncol.16(11), 3481–3482 (1998).
   PubMed Web of Science ®Google Scholar
• Gollerkeri A, Harrold L, Rose M, Jain D, Burtness BA. Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience. Int. J. Cancer93(1), 139–141 (2001).
   PubMed Web of Science ®Google Scholar
• Weiss RB, Donehower RC, Wiernik PH et al. Hypersensitivity reactions from taxol. J. Clin. Oncol.8(7), 1263–1268 (1990).
   PubMed Web of Science ®Google Scholar
• Gianni L, Vigano L, Locatelli A et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J. Clin. Oncol.15(5), 1906–1915 (1997).
   PubMed Web of Science ®Google Scholar
• Minotti G, Saponiero A, Licata S et al. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin. Cancer Res.7(6), 1511–1515 (2001).
   PubMed Web of Science ®Google Scholar
• Sparano JA, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. J. Clin. Oncol.17(12), 3828–3834 (1999).
   PubMed Web of Science ®Google Scholar
• Biganzoli L, Cufer T, Bruning P et al. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial. Cancer97(1), 40–45 (2003).
   PubMed Web of Science ®Google Scholar
• Conte PF, Baldini E, Gennari A et al. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J. Clin. Oncol.15(7), 2510–2517 (1997).
   PubMed Web of Science ®Google Scholar
• Gennari A, Salvadori B, Donati S et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J. Clin. Oncol.17(11), 3596–3602 (1999).
   PubMed Web of Science ®Google Scholar
• Baldini E, Prochilo T, Salvadori B et al. Multicenter randomized Phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety. Br. J. Cancer91(1), 45–49 (2004).
   PubMed Web of Science ®Google Scholar
• Sparano JA, O’Neill A, Schaefer PL, Falkson CI, Wood WC. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J. Clin. Oncol.18(12), 2369–2377 (2000).
   PubMed Web of Science ®Google Scholar
• Ayash LJ, Wright JE, Tretyakov O et al. Cyclophosphamide pharmokinetics; correlation with cardiac toxicity and tumour response. J. Clin. Oncol.10, 995–1000 (1992).
   PubMed Web of Science ®Google Scholar
• Dow E, Schulman H, Agura E. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant12, 169–172 (1993).
   PubMed Web of Science ®Google Scholar
• Steinherz LJ, Steinherz PG, Mangiacasale D et al. Cardiac changes with cyclophosphamide. Med. Pediatr. Oncol.9, 417–422 (1981).
   PubMedGoogle Scholar
• O'Connell TX, Berenbaum MC. Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide. Cancer Res.34(7), 1586–1591 (1974).
   PubMed Web of Science ®Google Scholar
• Hopkins HA, Betsill WL Jr, Hobson AS, Looney WB. Cyclophosphamide-induced cardiomyopathy in the rat. Cancer Treat. Rep.66(7), 1521–1527 (1982).
   PubMedGoogle Scholar
• Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch. Intern. Med.141(6), 758–763 (1981).
   PubMed Web of Science ®Google Scholar
• Cazin B, Gorin NC, Laporte JP et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer57(10), 2061–2069 (1986).
   PubMed Web of Science ®Google Scholar
• Tiersten A, Wo J, Jacobson C et al. Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer. Breast13(4), 341–346 (2004).
   PubMed Web of Science ®Google Scholar
• Kupari M, Volin L, Suokas A et al. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant5, 91–98 (1990).
   PubMed Web of Science ®Google Scholar
• Buja LM, Ferrans VJ, Graw RG Jr. Cardiac pathologic findings in patients treated with bone marrow transplantation. Hum. Pathol.7(1), 17–45 (1976).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Colvin OM, Aisaka K et al. Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity. Cancer Res.50(8), 2455–2462 (1990).
   PubMed Web of Science ®Google Scholar
• Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP. Ifosfamide cardiotoxicity in humans. Cancer Chemother. Pharmacol.24(6), 395–396 (1989).
   PubMed Web of Science ®Google Scholar
• Elias AD, Eder JP, Shea T, Begg CB, Frei E 3rd, Antman KH. High-dose ifosfamide with mesna uroprotection: a Phase I study. J. Clin. Oncol.8(1), 170–178 (1990).
   PubMed Web of Science ®Google Scholar
• Quezado ZM, Wilson WH, Cunnion RE et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann. Intern. Med.118(1), 31–36 (1993).
   PubMed Web of Science ®Google Scholar
• Talley RW, O’Bryan RM, Gutterman JU, Brownlee RW, McCredie KB. Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875) - phase I clinical study. Cancer Chemother. Rep.57(4), 465–471 (1973).
   PubMedGoogle Scholar
• Goldhirsch A, Joss R, Markwalder TM, Studer H, Brunner K. Acute cerebrovascular accident after treatment with cis-platinum and methylprednisolone. Oncology40(5), 344–345 (1983).
   PubMed Web of Science ®Google Scholar
• Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology42(5), 296–300 (1985).
   PubMed Web of Science ®Google Scholar
• Hashimi LA, Khalyl MF, Salem PA. Supraventricular tachycardia. A probable complication of platinum treatment. Oncology41(3), 174–175 (1984).
   PubMed Web of Science ®Google Scholar
• Canobbio L, Fassio T, Gasparini G et al. Cardiac arrhythmia: possible complication from treatment with cisplatin. Tumori72(2), 201–204 (1986).
   PubMed Web of Science ®Google Scholar
• Doll DC, List AF, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis. Ann. Intern. Med.105(1), 48–51 (1986).
   PubMed Web of Science ®Google Scholar
• Talcott JA, Herman TS. Acute ischemic vascular events and cisplatin. Ann. Intern. Med.107(1), 121–122 (1987).
   PubMed Web of Science ®Google Scholar
• Tomirotti M, Riundi R, Pulici S et al. Ischemic cardiopathy from cis-diamminedichloroplatinum (CDDP). Tumori70(3), 235–236 (1984).
   PubMed Web of Science ®Google Scholar
• Berliner S, Rahima M, Sidi Y et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest.8(6), 583–586 (1990).
   PubMed Web of Science ®Google Scholar
• Gerl A, Clemm C, Wilmanns W. Acute cerebrovascular event after cisplatin-based chemotherapy for testicular cancer. Lancet338(8763), 385–386 (1991).
   PubMed Web of Science ®Google Scholar
• Gamble GE, Tyrrell P. Acute stroke following cisplatin therapy. Clin. Oncol. (R. Coll. Radiol.)10(4), 274–275 (1998).
   PubMedGoogle Scholar
• Nichols CR, Roth BJ, Williams SD et al. No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J. Clin. Oncol.10(5), 760–765 (1992).
   PubMed Web of Science ®Google Scholar
• Rosenfeld CS, Broder LE. Cisplatin-induced autonomic neuropathy. Cancer Treat. Rep.68(4), 659–660 (1984).
   PubMedGoogle Scholar
• Nuver J, Smit AJ, van der Meer J et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J. Clin. Oncol.23(36), 9130–9137 (2005).
   PubMed Web of Science ®Google Scholar
• Nuver J, Smit AJ, Wolffenbuttel BH et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J. Clin. Oncol.23(16), 3718–3725 (2005).
   PubMed Web of Science ®Google Scholar
• Nuver J, Smit AJ, Sleijfer DT et al. Left ventricular and cardiac autonomic function in survivors of testicular cancer. Eur. J. Clin. Invest.35(2), 99–103 (2005).
   PubMed Web of Science ®Google Scholar
• Nuver J, Smit AJ, Sleijfer DT et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur. J. Cancer40(5), 701–706 (2004).
   PubMed Web of Science ®Google Scholar
• Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br. J. Cancer73(9), 1108–1114 (1996).
   PubMed Web of Science ®Google Scholar
• Gietema JA, de Vries EG, Sleijfer DT. Increased incidence of cardiovascular risk factors in cured testicular cancer patients. J. Clin. Oncol.10(10), 1652 (1992).
   PubMed Web of Science ®Google Scholar
• Strumberg D, Brugge S, Korn MW et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann. Oncol.13(2), 229–236 (2002).
   PubMed Web of Science ®Google Scholar
• Sagstuen H, Aass N, Fossa SD et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J. Clin. Oncol.23(22), 4980–4990 (2005).
   PubMed Web of Science ®Google Scholar
• Bissett D, Kunkeler L, Zwanenburg L et al. Long-term sequelae of treatment for testicular germ cell tumours. Br. J. Cancer.62(4), 655–659 (1990).
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Legha SS, Tashima CK et al. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat. Rep.62(7), 1005–1008 (1978).
   PubMedGoogle Scholar
• Monti E, Bossa R, Galatulas I, Favalli L, Villani F, Piccinini F. Interaction between doxorubicin and mitomycin C on mortality and myocardial contractility in guinea pig. Tumori69(2), 113–116 (1983).
   PubMed Web of Science ®Google Scholar
• Creech RH, Catalano RB, Shah MK, Dayal H. An effective low-dose mitomycin regimen for hormonal- and chemotherapy-refractory patients with metastatic breast cancer. Cancer51(6), 1034–1040 (1983).
   PubMed Web of Science ®Google Scholar
• Doyle LA, Ihde DC, Carney DN et al. Combination chemotherapy with doxorubicin and mitomycin C in non-small cell bronchogenic carcinoma. Severe pulmonary toxicity from q 3 weekly mitomycin C. Am. J. Clin. Oncol.7(6), 719–724 (1984).
   PubMed Web of Science ®Google Scholar
• Villani F, Comazzi R, Lacaita G et al. Possible enhancement of the cardiotoxicity of doxorubicin when combined with mitomycin C. Med. Oncol. Tumor. Pharmacother.2(2), 93–97 (1985).
   PubMedGoogle Scholar
• Verweij J, Funke-Kupper AJ, Teule GJ, Pinedo HM. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med. Oncol. Tumor Pharmacother.5(3), 159–163 (1988).
   PubMedGoogle Scholar
• White DA, Schwartzberg LS, Kris MG, Bosl GJ. Acute chest pain syndrome during bleomycin infusions. Cancer59(9), 1582–1585 (1987).
   PubMed Web of Science ®Google Scholar
• Durkin WJ, Pugh RP, Solomon J, Rosen P, Pajak TF, Bateman JR. Treatment of advanced lymphomas with bleomycin (NSC-125066). Oncology33(3), 140–145 (1976).
   PubMed Web of Science ®Google Scholar
• House KW, Simon SR, Pugh RP. Chemotherapy-induced myocardial infarction in a young man with Hodgkin's disease. Clin. Cardiol.15(2), 122–125 (1992).
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Frenning DH, Kennedy BJ. Coronary artery disease after treatment with bleomycin and vinblastine. Cancer Treat. Rep.64(10–11), 1159–1160 (1980).
   PubMedGoogle Scholar
• Schwarzer S, Eber B, Greinix H, Lind P. Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur. Heart J.12(6), 748–750 (1991).
   PubMed Web of Science ®Google Scholar
• Kanj SS, Sharara AI, Shpall EJ, Jones RB, Peters WP. Myocardial ischemia associated with high-dose carmustine infusion. Cancer68(9), 1910–1912 (1991).
   PubMed Web of Science ®Google Scholar
• Weinberger A, Pinkhas J, Sandbank U, Shaklai M, de Vries A. Endocardial fibrosis following busulfan treatment. JAMA231(5), 495 (1975).
   PubMed Web of Science ®Google Scholar
• Hartmann DW, Robinson WA, Mangalik A, Glode LM, Triebel F. Unanticipated side effects from treatment with high-dose mechlorethamine in patients with malignant melanoma. Cancer Treat. Rep.65(3–4), 327–328 (1981).
   PubMedGoogle Scholar
• Conrad ME. Cytarabine and cardiac failure. Am. J. Hematol.41, 143–144 (1992).
   Google Scholar
• Vaickus L, Letendre L. Pericarditis induced by high-dose cytarabine therapy. Arch. Intern. Med.144(9), 1868–1869 (1984).
   PubMed Web of Science ®Google Scholar
• Castleberry RP, Crist WM, Holbrook T et al. The cytosine arabinoside syndrome. Med. Pediatr. Oncol.9, 257 (1981).
   PubMedGoogle Scholar
• Illiano A, Barletta E, De Marino V et al. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a Phase II study. Anticancer Res.20(5C), 3999–4003 (2000).
   PubMed Web of Science ®Google Scholar
• Santini D, Tonini G, Abbate A et al. Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. Ann. Oncol.11(4), 479–481 (2000).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Cigolari S, Gallo C et al. MILES Investigators. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer31(2–3), 277–284 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrari D, Carbone C, Codeca C et al. Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity. Anticancer Drugs17(3), 359–361 (2006).
   PubMed Web of Science ®Google Scholar
• Van Besien K, Devine S, Wickrema A et al. Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant32(5), 471–476 (2003).
   PubMed Web of Science ®Google Scholar
• Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant28(1), 101–103 (2001).
   PubMed Web of Science ®Google Scholar
• Olivieri A, Corvatta L, Montanari M et al. Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells. Bone Marrow Transplant21(10), 1049–1053 (1998).
   PubMed Web of Science ®Google Scholar
• Grem JL, King SA, Chun HG, Grever MR. Cardiac complications observed in elderly patients following 2'-deoxycoformycin therapy. Am. J. Hematol.38(3), 245–247 (1991).
   PubMed Web of Science ®Google Scholar
• Helland S, Ueland PM. Effect of 2'-deoxycoformycin infusion on S-adenosylhomocysteine hydrolase and the amount of S-adenosylhomocysteine and related compounds in tissues of mice. Cancer Res.43(9), 4142–4147 (1983).
   PubMed Web of Science ®Google Scholar
• Ho AD, Thaler J, Mandelli F et al. Response to pentostatin in hairy-cell leukemia refractory to interferon-α. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J. Clin. Oncol.7(10), 1533–1538 (1989).
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Yul LS, Oda T et al. Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia. Leuk. Res.10(8), 989–993 (1986).
   PubMed Web of Science ®Google Scholar
• Mandel EM, Lewinski U, Djaldetti M. Vincristine-induced myocardial infarction. Cancer36(6), 1979–1982 (1975).
   PubMed Web of Science ®Google Scholar
• Somers G, Abramov M, Witter M, Naets JP. Myocardial infarction: a complication of vincristine treatment? Lancet2(7987), 690 (1976).
   PubMed Web of Science ®Google Scholar
• Harris AL, Wong C. Myocardial ischaemia, radiotherapy, and vinblastine. Lancet1(8223), 787 (1981).
   PubMed Web of Science ®Google Scholar
• Kantor AF, Greene MH, Boice JD, Fraumeni JF Jr, Flannery JT. Are vinca alkaloids associated with myocardial infarction? Lancet1(8229), 1111 (1981).
   PubMed Web of Science ®Google Scholar
• Yancey RS, Talpaz M. Vindesine-associated angina and ECG changes. Cancer Treat. Rep.66(3), 587–589 (1982).
   PubMedGoogle Scholar
• Roca E, Bruera E, Politi PM et al. Vinca alkaloid-induced cardiovascular autonomic neuropathy. Cancer Treat. Rep.69(2), 149–151 (1985).
   PubMedGoogle Scholar
• Subar M, Muggia FM. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat. Rep.70(5), 690–691 (1986).
   PubMedGoogle Scholar
• Cargill RI, Boyter AC, Lipworth BJ. Reversible myocardial ischaemia following vincristine containing chemotherapy. Respir. Med.88(9), 709–710 (1994).
   PubMed Web of Science ®Google Scholar
• Bergeron A, Raffy O, Vannetzel JM. Myocardial ischemia and infarction associated with vinorelbine. J. Clin. Oncol.13(2), 531–532 (1995).
   PubMed Web of Science ®Google Scholar
• Zabernigg A, Gattringer C. Myocardial infarction associated with vinorelbine (Navelbine). Eur. J. Cancer32A(9), 1618–1619 (1996).
   PubMed Web of Science ®Google Scholar
• Lapeyre-Mestre M, Gregoire N, Bugat R, Montastruc JL. Vinorelbine-related cardiac events: a meta-analysis of randomized clinical trials. Fundam. Clin. Pharmacol.18(1), 97–105 (2004).
   PubMed Web of Science ®Google Scholar
• Airey CL, Dodwell DJ, Joffe JK, Jones WG. Etoposide-related myocardial infarction. Clin. Oncol. (R. Coll. Radiol.)7(2), 135 (1995).
   PubMedGoogle Scholar
• Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol.23(13), 2900–2902 (2005).
   PubMed Web of Science ®Google Scholar
• Chien KR. Herceptin and the heart – a molecular modifier of cardiac failure. N. Engl. J. Med.354(8), 789–790 (2006).
   PubMed Web of Science ®Google Scholar
• Chien KR. Stress pathways and heart failure. Cell98(5), 555–558 (1999).
   PubMed Web of Science ®Google Scholar
• Ewer MS, Gibbs HR, Swafford J, Benjamin RS. Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact? Semin. Oncol.26(4 Suppl. 12), 96–101 (1999).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16), 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353(16), 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood104(3), 655–658 (2004).
   PubMed Web of Science ®Google Scholar
• Lundin J, Kennedy B, Dearden C, Dyer MJ, Osterborg A. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome. Blood105(10), 4148–4149 (2005).
   PubMed Web of Science ®Google Scholar
• Lundin J, Hagberg H, Repp R et al. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood101(11), 4267–4272 (2003).
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Seymour JF, Wolf M et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur. J. Haematol.71(4), 250–256 (2003).
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood103(8), 2920–2924 (2004).
   PubMed Web of Science ®Google Scholar
• Oshima K, Sakata-Yanagimoto M, Asano-Mori Y et al. Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab. Bone Marrow Transplant36(9), 821–824 (2005).
   PubMed Web of Science ®Google Scholar
• D’Adamo DR, Anderson SE, Albritton K et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol.23(28), 7135–7142 (2005).
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. (2006) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Cooney MM, Radivoyevitch T, Dowlati A et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose Phase I study in patients with advanced cancer. Clin. Cancer Res.10(1 Pt 1), 96–100 (2004).
   PubMed Web of Science ®Google Scholar
• Beerepoot LV, Radema SA, Witteveen EO et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J. Clin. Oncol.24(10), 1491–1498 (2006).
   PubMed Web of Science ®Google Scholar
• Bilenker JH, Flaherty KT, Rosen M et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin. Cancer Res.11(4), 1527–1533 (2005).
   PubMed Web of Science ®Google Scholar
• Lee RE, Lotze MT, Skibber JM et al. Cardiorespiratory effects of immunotherapy with interleukin-2. J. Clin. Oncol.7(1), 7–20 (1989).
   PubMed Web of Science ®Google Scholar
• Margolin KA, Rayner AA, Hawkins MJ et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J. Clin. Oncol.7(4), 486–498 (1989).
   PubMed Web of Science ®Google Scholar
• Yang JC, Topalian SL, Parkinson D et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J. Clin. Oncol.12(8), 1572–1576 (1994).
   PubMed Web of Science ®Google Scholar
• Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol.21(16), 3127–3132 (2003).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol.23(1), 133–141 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang J, Yu ZX, Hilbert SL et al. Cardiotoxicity of human recombinant interleukin-2 in rats. A morphological study. Circulation87(4), 1340–1353 (1993).
   PubMed Web of Science ®Google Scholar
• Atkins MB, Sparano J, Fisher RI et al. Randomized Phase II trial of high-dose interleukin-2 either alone or in combination with interferon α-2b in advanced renal cell carcinoma. J. Clin. Oncol.11(4), 661–670 (1993).
   PubMed Web of Science ®Google Scholar
• Dickson D. Deaths halt interferon trials in France. Science218(4574), 772 (1982).
   PubMed Web of Science ®Google Scholar
• Martino S, Samal BA, Sahn YH. Reversible cardiac arrhythmia in a breast cancer patient treated with recombinant α interferon. Breast Cancer Res. Treat.5(3), 327–329 (1985).
   PubMed Web of Science ®Google Scholar
• Martino S, Ratanatharathorn V, Karanes C, Samal BA, Sohn YH, Rudnick SA. Reversible arrhythmias observed in patients treated with recombinant α 2 interferon. J. Cancer Res. Clin. Oncol.113(4), 376–378 (1987).
   PubMed Web of Science ®Google Scholar
• Cohen MC, Huberman MS, Nesto RW. Recombinant α 2 interferon-related cardiomyopathy. Am. J. Med.85(4), 549–551 (1988).
   PubMed Web of Science ®Google Scholar
• Deyton LR, Walker RE, Kovacs JA et al. Reversible cardiac dysfunction associated with interferon α therapy in AIDS patients with Kaposi's sarcoma. N. Engl. J. Med.321(18), 1246–1249 (1989).
   PubMed Web of Science ®Google Scholar
• Zimmerman S, Adkins D, Graham M et al. Irreversible, severe congestive cardiomyopathy occurring in association with interferon α therapy. Cancer Biother.9(4), 291–299 (1994).
   PubMedGoogle Scholar
• Mattson K, Niiranen A, Pyrhonen S, Farkkila M, Cantell K. Recombinant interferon γ treatment in non-small cell lung cancer. Antitumour effect and cardiotoxicity. Acta Oncol.30(5), 607–610 (1991).
   PubMed Web of Science ®Google Scholar
• Sartori M, Andorno S, La Terra G et al. Assessment of interferon cardiotoxicity with quantitative radionuclide angiocardiography. Eur. J. Clin. Invest.25(1), 68–70 (1995).
   PubMed Web of Science ®Google Scholar
• Salman H, Bergman M, Bessler H, Alexandrova S, Djaldetti M. The effect of interferon on mouse myocardial capillaries: an ultrastructural study. Cancer85(6), 1375–1379 (1999).
   PubMed Web of Science ®Google Scholar
• Tallman MS, Andersen JW, Schiffer CA et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood95(1), 90–95 (2000).
   PubMed Web of Science ®Google Scholar
• Huang CH, Chen WJ, Wu CC, Chen YC, Lee YT. Complete atrioventricular block after arsenic trioxide treatment in an acute promyelocytic leukemic patient. Pacing Clin. Electrophysiol.22(6 Pt 1), 965–967 (1999).
   PubMed Web of Science ®Google Scholar
• Unnikrishnan D, Dutcher JP, Varshneya N et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood97(5), 1514–1516 (2001).
   PubMed Web of Science ®Google Scholar
• Naito K, Kobayashi M, Sahara N et al. Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy. Int. J. Hematol.83(4), 318–323 (2006).
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Yoshida H, Shigeno K et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann. Intern. Med.133(11), 881–885 (2000).
   PubMed Web of Science ®Google Scholar
• Westervelt P, Brown RA, Adkins DR et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood98(2), 266–271 (2001).
   PubMed Web of Science ®Google Scholar
• Vey N, Bosly A, Guerci A et al. Arsenic trioxide in patients with myelodysplastic syndromes: a Phase II multicenter study. J. Clin. Oncol.24(16), 2465–2471 (2006).
   PubMed Web of Science ®Google Scholar
• Schiller GJ, Slack J, Hainsworth JD et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J. Clin. Oncol.24(16), 2456–2464 (2006).
   PubMed Web of Science ®Google Scholar
• Siu CW, Au WY, Yung C et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood108(1), 103–106 (2006).
   PubMed Web of Science ®Google Scholar
• Ficker E, Kuryshev YA, Dennis AT et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol. Pharmacol.66(1), 33–44 (2004).
   PubMed Web of Science ®Google Scholar
• Drolet B, Simard C, Roden DM. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation109(1), 26–29 (2004).
   PubMed Web of Science ®Google Scholar
• Fragasso G, Pastore MR, Vicari A, Chierchia SL, Pozza G. Myocardial infarction in a patient with acute lymphoblastic leukemia during L-asparaginase therapy. Am. J. Hematol.48(2), 136–137 (1995).
   PubMed Web of Science ®Google Scholar
• Saviola A, Luppi M, Potenza L et al. Myocardial ischemia in a patient with acute lymphoblastic leukemia during L-asparaginase therapy. Eur. J. Haematol.72(1), 71–72 (2004).
   PubMed Web of Science ®Google Scholar
• Oettgen HF, Stephenson PA, Schwartz MK et al. Toxicity of E. coli L-asparaginase in man. Cancer25(2), 253–278 (1970).
   PubMedGoogle Scholar
• Zollner N, Heimstadt P. Effects of a single administration of L-asparaginase on serum lipids. Nutr. Metab.13(6), 344–348 (1971).
   PubMedGoogle Scholar
• Cremer P, Lakomek M, Beck W, Prindull G. The effect of L-asparaginase on lipid metabolism during induction chemotherapy of childhood lymphoblastic leukaemia. Eur. J. Pediatr.147(1), 64–67 (1988).
   PubMed Web of Science ®Google Scholar
• Favrot MC, Dellamonica C, Souillet G. Study of blood lipids in 30 children with a malignant hematological disease or carcinoma. Biomed. Pharmacother.38(1), 55–59 (1984).
   PubMed Web of Science ®Google Scholar
• Steinherz PG. Transient, severe hyperlipidemia in patients with acute lymphoblastic leukaemia treated with prednisone and asparaginase. Cancer74(12), 3234–3239 (1994).
   PubMed Web of Science ®Google Scholar
• Parsons SK, Skapek SX, Neufeld EJ et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood89(6), 1886–1895 (1997).
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J. Support Oncol.1(3), 194–205 (2003).
   PubMedGoogle Scholar
• Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM. A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer95(8), 1629–1636 (2002).
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Hoffmann F et al. A systematic review of Phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br. J. Haematol.132(5), 584–593 (2006).
   PubMed Web of Science ®Google Scholar
• Gullestad L, Ueland T, Fjeld JG et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation112(22), 3408–3414 (2005).
   PubMed Web of Science ®Google Scholar
• Gullestad L, Semb AG, Holt E et al. Effect of thalidomide in patients with chronic heart failure. Am. Heart J.144(5), 847–850 (2002).
   PubMed Web of Science ®Google Scholar
• Hamlin RL, Kijtawornrat A, Keene BW et al. Effects of thalidomide on QTc, inotropy, and lusitropy in the isolated guinea pig heart. Cardiovasc. Toxicol.4(1), 29–36 (2004).
   PubMedGoogle Scholar